Matched placebo for product clinical trials

A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open-label long-term extension period

This study looks at a new drug, SAR443820, for multiple sclerosis (MS). Researchers want to see if it lowers a marker in the blood called neurofilament, which can show nerve damage. It's a Phase 2 trial, meaning it's still in earlier stages of testing.